TD Cowen issued a buy rating and price target for Dexcom on October 9, 2026.
1 report, 1 independent
Updated Fri 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen issued a buy rating and price target for Dexcom on October 9, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Dexcom
company that develops, manufactures and distributes continuous glucose monitoring systems
Nothing else this week.
-
TD Cowen
American investment bank
Related events
- MarketBeat reported that TD Cowen increased its price objective and gave a buy rating for an unnamed company.
- TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., while various institutional investors bought into the company.
- TD Cowen increased its target price and issued a buy rating for Butterfly Network, with MarketBeat aggregating the data.
- TD Cowen, Royal Bank of Canada, and Morgan Stanley all raised price targets and ratings for Ralliant.
- Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.